MAPT and Alzheimer disease: For example, evidence indicates that patients with AD who exhibit lower tau tracer uptake on positron emission tomography (PET) scans respond better to Aβ-targeting monoclonal antibody therapies, suggesting that this group may have the most favorable risk–benefit ratio for this treatment4,5.